Hernández-Collazo AA, Villanueva-Quintero G, Rodríguez-Castellanos MA, Poletti-Vázquez ED, Alvarado-Navarro A

Language: Spanish
References: 15
Page: 427-431
PDF size: 174.75 Kb.

ABSTRACT

Introduction: Hyperuricemia is common in patients with psoriasis. Uric acid elevation in psoriasis has been suggested to be strongly associated with cardiovascular morbidity. Objective: To determine the relationship between uric acid levels and clinical severity as measured by the Psoriasis Area Severity Index (PASI), body surface area (BSA) and static Physician’s Global Assessment (sPGA) in patients with plaque psoriasis and nail comorbidities and psoriatic arthritis. Method: Determination of serum uric acid in 45 patients with plaque psoriasis and 45 controls matched by gender, age and body mass index; measurement of patient clinical severity indices and presence of nail and joint manifestations. Results: Patients with psoriasis had higher levels of uric acid (7.03 ± 1.47 versus 5.32 ± 1.17, p ‹ 0.01), and higher prevalence of asymptomatic hyperuricemia than controls (68% versus 17.8%, p ‹ 0.01). There was significant proportional correlation between PASI-determined severity and uric acid (r² = 0.70), and between joint manifestations and hyperuricemia in patients with plaque psoriasis (p ‹ 0.01; OR = 2.85, 95% CI = 1.52-5.33). Conclusions: Serum uric acid levels had a proportional correlation with PASI and were associated with joint manifestations in patients with plaque psoriasis.

REFERENCES

1. Gudjonsson JE, Elder JT. Psoriasis: Epidemiology. Clin Dermatol. 2007;25(6):535-546.

2. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van-Voorhees AS, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76(3):377-390.

3. Krueger J, Bowcock A. Psoriasis pathophysiology: Current concepts of pathogenesis. Ann Rheum Dis. 2005;64(Suppl 2):ii30-ii36.

4. Rivas-Bejarano JJ, Valdecantos WC. Psoriasis as autoinflammatory disease. Dermatol Clin. 2013;31(3):445-460.

5. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van- Voorhees AS, et al. Psoriasis and comorbid diseases: implicationsfor management. J Am Acad Dermatol. 2017;76(3):393-403.

6. Kwon HH, Kwon IH, Choi JW, Youn JI. Cross-sectional study on the correlation of serum uric acid with disease severity in Korean patients with psoriasis. Clin Exp Dermatol. 2011;36:473-478.

7. Lobitz W, Brunsting L. Unpublished studies. En: Ormsby OS, Montgomery H. Diseases of the skin. USA: Lea and Febiger; 1948.

8. Gisondi P, Targher G, Cagalli A, Girolomi G. Hyperuricemia in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;70(1):127-130.

9. Li X, Miao X, Wang H, Wang Y, Li F, Yang Q, et al. Association of serum uric acid levels in psoriasis: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(19):e3676.

10. González-Gay MA, González-Juanatey C, Vázquez-Rodríguez TR, Gómez- Acebo I, Miranda-Filloy JA, Paz-Carreira J, et al. Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum. 2009;39(3):157-162.

11. Isha, Jain VK, Lal H. C-reactive protein and uric acid levels in patients with psoriasis. Indian J Clin Biochem. 2011;26(3):309-311.

12. Henseler T, Schmitt-Rau K. A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis. Int J Dermatol. 2008;47(10):1019-1023.

13. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol. 2004;51(4):563-569.

14. Torre-Alonso JC. Utilidad y aplicación en la práctica clínica de los criterios de CASPAR. Reumatol Clin. 2010;6:18-21.

15. Llamazares-Azuara L, Rodríguez-Martínez M, De-La-Cruz-Mendoza E, Torres-Ruvalcaba A, Flores-Sánchez J. Prevalencia de hiperuricemia, resistencia a la insulina, y dislipidemia en jóvenes de 17 a 23 años. Bioquimia. 2007;32:134.